Literature DB >> 1416898

Inhibition of intrahepatic hepatitis B virus replication by antiviral drugs in a novel transgenic mouse model.

T Nagahata1, K Araki, K Yamamura, K Matsubara.   

Abstract

Transgenic mice which carry the integrated human hepatitis B virus (HBV) genome and produce HBV particles in the liver were treated with antiviral compounds, and the amount of viral DNA in the liver and serum was monitored by Southern analyses. Mouse alpha interferon (200,000 U per injection, twice daily for 3 days) and a novel nucleoside, oxetanocin G (15 mg/kg of body weight per injection, twice daily for 7 days), inhibited viral DNA synthesis in the liver almost completely. This animal model should prove useful in evaluating anti-HBV agents.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1416898      PMCID： PMC192434          DOI： 10.1128/AAC.36.9.2042

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Derivatives of oxetanocin: oxetanocins H, X and G, and 2-aminooxetanocin A.

Authors:  N Shimada; S Hasegawa; S Saito; T Nishikiori; A Fujii; T Takita
Journal:  J Antibiot (Tokyo)       Date:  1987-12       Impact factor: 2.649

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine arabinoside 5'-monophosphate, adenine arabinoside, and phosphonoacetic acid.

Authors:  E R Kern; J T Richards; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

4.  An in vitro system for screening anti-hepatitis B virus drugs.

Authors:  K Ueda; T Tsurimoto; T Nagahata; O Chisaka; K Matsubara
Journal:  Virology       Date:  1989-03       Impact factor: 3.616

5.  pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells.

Authors:  I M Kerr; R E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Mechanisms of action of human interferons. Induction of 2'5'-oligo(A) polymerase.

Authors:  C Baglioni; P A Maroney
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

7.  Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.

Authors:  R P Beasley; L Y Hwang; C C Lin; C S Chien
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

8.  Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro.

Authors:  T Yokota; K Konno; E Chonan; S Mochizuki; K Kojima; S Shigeta; E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

9.  Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection.

Authors:  K Hirota; A H Sherker; M Omata; O Yokosuka; K Okuda
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

Review 10.  The hepatitis B virus.

Authors:  P Tiollais; C Pourcel; A Dejean
Journal:  Nature       Date:  1985 Oct 10-16       Impact factor: 49.962
View more
  3 in total

1.  Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma.

Authors:  J Petersen; M Dandri; S Gupta; C E Rogler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

2.  Effect of oxetanocin G, a novel nucleoside analog, on DNA synthesis by hepatitis B virus virions.

Authors:  T Nagahata; M Kitagawa; K Matsubara
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

3.  Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.

Authors:  L D Condreay; R W Jansen; T F Powdrill; L C Johnson; D W Selleseth; M T Paff; S M Daluge; G R Painter; P A Furman; M N Ellis
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.